A Multicenter Prospective Observational Study on Vertebral Fracture Risk Stratification in Patients With Vertebral Metastases
Valid-METASTRA
1 other identifier
observational
300
4 countries
4
Brief Summary
Vertebral fracture is a common clinically significant skeletal related event in cancer patients. Stratification of patients diagnosed with one or more vertebral metastases according to the risk of pathological fracture is an unresolved problem despite the fact that fractures strongly influence the quality of life (QoL) and also the overall survival. The multidimensional nature and the strong patient specificity of the risk for fracture have not been considered in previously published risk estimation models and these methods were developed and validated only on retrospective data focusing on prevalence of life-time fracture which is not really relevant at the time of the diagnosis of a vertebral metastasis. To overcome these shortcomings, the METASTRA models (METASTRA-AI and METASTRA-VPH) and the decision support system (METASTRA-DSS) are developed considering the highest possible level of patient specificity to stratify the individuals according to their risk for fracture in a clinically considerable period (within next 6 months). The prospective data collection and analysis will provide reliability and validity results on the performance of METASTRA tools as well as structured information on user's experience helping the future integration of the developed patient-specific stratification tool into the everyday clinical practice. The study is a prospective clinical data collection from minimum 200 patients to determine the validity (i.e. Precision) in fracture risk stratification of the METASTRA-AI and METASTRA-VPH computational models and to determine the reliability of METASTRA-AI and METASTRA-VPH as well as human decision making process in patient stratification.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2025
Typical duration for all trials
4 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 28, 2025
CompletedStudy Start
First participant enrolled
April 1, 2025
CompletedFirst Posted
Study publicly available on registry
April 4, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
August 1, 2027
April 4, 2025
March 1, 2025
2 years
March 28, 2025
March 28, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
new vertebral fracture
in 6 months
Study Arms (1)
Patients with vertebral metastasis in ThL region
Patient diagnosed with a metastatic tumor in the thoracic and/or lumbar spine (one or more vertebral metastases in the spinal region between T1 and L5 vertebrae)
Eligibility Criteria
Patient diagnosed with a metastatic tumor in the thoracic and/or lumbar spine (one or more vertebral metastases in the spinal region between T1 and L5 vertebrae)
You may qualify if:
- Patient 18 years or older
- Patient diagnosed with a metastatic tumor in the thoracic and/or lumbar spine (one or more vertebral metastases in the spinal region between T1 and L5 vertebrae)
- Min. 1 vertebra is potentially unstable based on SINS score (SINS is 7-12) and it has not been surgically stabilized previously (level of interest - LOI)
- Adjacent vertebrae are not surgically stabilized at the time of the enrollment
- Patient willing to complete 6-month follow-up
- Patient is willing and able to provide written informed consent after the nature of the study has been explained:
- Ability to understand the content of the patient information/ ICF
- Willingness and ability to participate in the study according to the protocol
- Signed and dated EC approved written informed consent
You may not qualify if:
- Poor general status at baseline (Karnofsky scale less than 40%)
- Expected life expectancy is less than 3 months at baseline
- Spinal infection
- Ongoing litigation
- Participation in investigational clinical study at the same time or within 3 months
- Vertebral lesion/metastasis from a hematologic condition (e.g. multiple myeloma)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (4)
Department of Neurosurgery Charité Berlin
Berlin, Germany
Buda Health Center
Budapest, 1126, Hungary
IRCCS Istituto Ortopedico Rizzoli
Bologna, Italy
University Medical Center Utrecht
Utrecht, Netherlands
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 6 Months
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 28, 2025
First Posted
April 4, 2025
Study Start
April 1, 2025
Primary Completion (Estimated)
April 1, 2027
Study Completion (Estimated)
August 1, 2027
Last Updated
April 4, 2025
Record last verified: 2025-03
Data Sharing
- IPD Sharing
- Will not share